PMID- 15507883
OWN - NLM
STAT- MEDLINE
DCOM- 20050113
LR  - 20151119
IS  - 0031-0808 (Print)
IS  - 0031-0808 (Linking)
VI  - 46
IP  - 2
DP  - 2004 Jun
TI  - Omalizumab: efficacy in allergic disease.
PG  - 141-8
AB  - Asthma and allergic rhinitis are common conditions that have a substantial impact 
      on patient quality of life, severely disrupting physical, emotional and social 
      functioning. These diseases share many pathophysiological characteristics and 
      recent research has provided evidence that a strong causal relationship exists 
      between allergy and both asthma and allergic rhinitis. As a root cause of 
      allergic diseases of the airways, immunoglobulin E (IgE) represents an 
      appropriate target for the development of new therapies. Omalizumab (Xolair) is a 
      recombinant humanized monoclonal anti-IgE antibody that has demonstrated efficacy 
      in allergic asthma and other IgE-related allergic illnesses. In three pivotal, 
      placebo-controlled trials in patients with moderate-to-severe allergic asthma, 
      omalizumab provided effective disease control, significantly reducing 
      exacerbations while improving quality of life. Additionally, omalizumab reduced 
      the need for unscheduled outpatient visits, emergency room visits and 
      hospitalizations. Omalizumab was particularly useful as add-on treatment for 
      patients with poorly controlled severe asthma. Similar benefits were reported in 
      patients with seasonal or perennial allergic rhinitis. Omalizumab significantly 
      improved disease symptoms and reduced the use of rescue antihistamines. In 
      patients with concomitant asthma and perennial allergic rhinitis, omaliuzumab 
      significantly prevented asthma exacerbations and improved quality of life 
      compared with placebo. Taken together, these results suggest that omalizumab 
      represents an important clinical advance in the management of allergic disease.
FAU - Spector, S
AU  - Spector S
AD  - University of California, Los Angeles, CA 90025, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Panminerva Med
JT  - Panminerva medica
JID - 0421110
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/immunology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/drug therapy/etiology
MH  - Humans
MH  - Hypersensitivity/complications/*drug therapy/immunology
MH  - Immunoglobulin E/immunology
MH  - Omalizumab
MH  - Randomized Controlled Trials as Topic
MH  - Rhinitis/drug therapy/etiology
MH  - Treatment Outcome
RF  - 39
EDAT- 2004/10/28 09:00
MHDA- 2005/01/14 09:00
CRDT- 2004/10/28 09:00
PHST- 2004/10/28 09:00 [pubmed]
PHST- 2005/01/14 09:00 [medline]
PHST- 2004/10/28 09:00 [entrez]
PST - ppublish
SO  - Panminerva Med. 2004 Jun;46(2):141-8.